FI110843B - Förfarande för framställning av ett hepatitvaccin innehållande 3-O-deacylererad monofosforyllipid A - Google Patents
Förfarande för framställning av ett hepatitvaccin innehållande 3-O-deacylererad monofosforyllipid A Download PDFInfo
- Publication number
- FI110843B FI110843B FI944442A FI944442A FI110843B FI 110843 B FI110843 B FI 110843B FI 944442 A FI944442 A FI 944442A FI 944442 A FI944442 A FI 944442A FI 110843 B FI110843 B FI 110843B
- Authority
- FI
- Finland
- Prior art keywords
- hepatitis
- hbsag
- antigen
- mpl
- vaccine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32411—Hepatovirus, i.e. hepatitis A virus
- C12N2770/32434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Claims (16)
1. Förfarande för framställning av ett vaccin soin är effektivt vid förebyggande eller behandling av hepatit- 5 infektion, kännetecknat av att en hepatitis-antigen blandas tillsammans med en 3-O-deacylerad monofosforyllipid A och en lämplig bärare.
2. Förfarande enligt patentkrav 1, kännetecknat av att 10 bäraren är alun.
3. Förfarande enligt patentkrav 1, kännetecknat av att bäraren är en oija-i-vatten emulsion eller nägon annan lipidbaserad vehikel. 15
4. Förfarande enligt vilket som heist av föregäende patentkrav, kännetecknat av att hepatitis-antigenen är en antigen mot hepatitis A. 20
5. Förfarande enligt patentkrav 4, kännetecknat av att hepatitis A -antigenen är en inaktiverad helcellkomposition ;\· härledd frän HM-175-stammen.
6. Förfarande enligt vilket som heist av patentkraven 1-3, "I 25 kännetecknat av att hepatitis-antigenen är en antigen mot hepatitis B.
’·' 7. Förfarande enligt patentkrav 6, kännetecknat av att antigenen innefattar en hepatitis B -ytantigen (HBsAg) eller 30 en variant därav.
’·.· 8. Förfarande enligt patentkrav 7, kännetecknat av att HBsAg innefattar S-antigenen av HBsAg (226 aminosyror). » · ‘;’(j 35
9. Förfarande enligt patentkrav 8, kännetecknat av att HBsAg ytterligare innefattar en pre-S-sekvens. 110843
10. Förfarande enligt patentkrav 8 eller 9, kännetecknat av att HBsAg är en kompositpartikel med formeln (L*, S) väri L* betecknar ett modifierat L-protein av hepatitis B-virus med en aminosyrasekvens innefattande resterna 12-52 följda av 5 resterna 133-145 följda av resterna 175-400 av L-proteinet och S betecknar S-proteinet av HBsAg.
11. Förfarande enligt vilket som heist av patentkraven 6-10, kännetecknat av att vaccinet ytterligare innefattar en 10 hepatitis A -antigen.
12. Förfarande enligt vilket som heist av föregäende patentkrav, kännetecknat av att vaccinet innefatter en eller flera hepatitis-antigener och atminstone en annan komponent 15 vald bland icke-hepatitis-antigener och som ger skydd mot ett eller flera av följande: difteri, tetanus, pertussis, Haemophilus-influensa b (Hib) och polio.
13. Förfarande enligt patentkrav 12, kännetecknat av att 20 vaccinet är valt bland en DTP (difteri-tetanus-pertussis)- HBsAg-kombination, en Hib-HBsAg-kombination, en DTP-Hib-, , HBsAg-kombination och en IPV (inaktiverat poliovaccin) -DTP- • Hib-HBsAg-kombination. 25
14. Förfarande enligt patentkrav 12, kännetecknat av att I; vaccinet ytterligare innefattar en hepatitis A -antigen. , l » »
15. Förfarande enligt vilket som heist av patentkraven 1 -3, kännetecknat av att hepatitis-antigenen är en antigen mot 30 hepatitis C eller hepatitis D eller hepatitis E.
. . 16. Förfarande enligt vilket som heist av föregäende patent- krav, kännetecknat av att den 3-O-deacylerade monofosforyl-'*··_ lipiden A är närvarande i en mängd av 10 - 100 pg per dos. t » » · * » i » «
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9206789 | 1992-03-27 | ||
| GB9206797 | 1992-03-27 | ||
| GB929206788A GB9206788D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
| GB9206788 | 1992-03-27 | ||
| GB929206797A GB9206797D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
| GB929206789A GB9206789D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
| GB929206786A GB9206786D0 (en) | 1992-03-27 | 1992-03-27 | Vaccine |
| GB9206786 | 1992-03-27 | ||
| EP9300712 | 1993-03-24 | ||
| PCT/EP1993/000712 WO1993019780A1 (en) | 1992-03-27 | 1993-03-24 | Hepatitis vaccines containing 3-o-deacylated monophoshoryl lipid a |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI944442A FI944442A (sv) | 1994-09-26 |
| FI944442A0 FI944442A0 (sv) | 1994-09-26 |
| FI110843B true FI110843B (sv) | 2003-04-15 |
Family
ID=27450853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI944442A FI110843B (sv) | 1992-03-27 | 1994-09-26 | Förfarande för framställning av ett hepatitvaccin innehållande 3-O-deacylererad monofosforyllipid A |
Country Status (28)
| Country | Link |
|---|---|
| EP (1) | EP0633784B2 (sv) |
| JP (1) | JP3470719B2 (sv) |
| KR (1) | KR100270134B1 (sv) |
| CN (1) | CN1072963C (sv) |
| AP (1) | AP570A (sv) |
| AT (1) | ATE146678T1 (sv) |
| AU (4) | AU3751693A (sv) |
| CA (1) | CA2132833C (sv) |
| CZ (1) | CZ283424B6 (sv) |
| DE (1) | DE69306940T3 (sv) |
| DK (1) | DK0633784T4 (sv) |
| ES (1) | ES2098029T5 (sv) |
| FI (1) | FI110843B (sv) |
| GR (1) | GR3022174T3 (sv) |
| HK (1) | HK1003218A1 (sv) |
| HU (1) | HU221253B1 (sv) |
| IL (1) | IL105161A (sv) |
| MA (1) | MA22842A1 (sv) |
| MY (1) | MY111880A (sv) |
| NO (1) | NO309458B1 (sv) |
| NZ (1) | NZ249868A (sv) |
| RU (1) | RU2121849C1 (sv) |
| SA (1) | SA93130573B1 (sv) |
| SG (1) | SG48375A1 (sv) |
| SI (1) | SI9300149B (sv) |
| SK (1) | SK280160B6 (sv) |
| UA (1) | UA44688C2 (sv) |
| WO (1) | WO1993019780A1 (sv) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9105992D0 (en) * | 1991-03-21 | 1991-05-08 | Smithkline Beecham Biolog | Vaccine |
| ES2162139T5 (es) * | 1993-03-23 | 2008-05-16 | Smithkline Beecham Biologicals S.A. | Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado. |
| US6488934B1 (en) | 1995-02-25 | 2002-12-03 | Smithkline Beecham Biologicals S.A. | Hepatitis B vaccine |
| GB9503863D0 (en) * | 1995-02-25 | 1995-04-19 | Smithkline Beecham Biolog | Vaccine compositions |
| GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| NZ506602A (en) * | 1998-03-09 | 2003-02-28 | Smithkline Beecham Biolog S | Combined vaccine compositions against hepatitis B virus and herpes simplex virus and possibly also epstein bar virus, hepatitis A & C viruses, human papilloma virus, varicella zoster virus, human cytomegalovirus, and toxoplasma gondii |
| US6306404B1 (en) | 1998-07-14 | 2001-10-23 | American Cyanamid Company | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| GB9822714D0 (en) * | 1998-10-16 | 1998-12-09 | Smithkline Beecham Sa | Vaccines |
| US7357936B1 (en) * | 1998-10-16 | 2008-04-15 | Smithkline Beecham Biologicals, Sa | Adjuvant systems and vaccines |
| FI108150B (sv) | 1999-02-15 | 2001-11-30 | Sulzer Pumpen Ag | Förfarande och anläggning för behandling av en massa |
| US6635261B2 (en) | 1999-07-13 | 2003-10-21 | Wyeth Holdings Corporation | Adjuvant and vaccine compositions containing monophosphoryl lipid A |
| GB9921147D0 (en) | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
| KR101505496B1 (ko) | 2004-09-22 | 2015-03-25 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 스태필로코쿠스에 대한 예방접종에 사용하기 위한 면역원성 조성물 |
| EP1863529A1 (en) | 2005-03-23 | 2007-12-12 | GlaxoSmithKline Biologicals S.A. | Novel composition |
| US20110180430A1 (en) | 2005-11-04 | 2011-07-28 | Novartis Vaccines And Diagnostics Srl | Adjuvanted influenza vaccines including cytokine-inducing agents |
| EP2368572B1 (en) | 2005-11-04 | 2020-03-04 | Seqirus UK Limited | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| NZ567978A (en) | 2005-11-04 | 2011-09-30 | Novartis Vaccines & Diagnostic | Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant |
| NZ568211A (en) | 2005-11-04 | 2011-11-25 | Novartis Vaccines & Diagnostic | Influenza vaccines including combinations of particulate adjuvants and immunopotentiators |
| EP1973564B1 (en) | 2005-12-22 | 2016-11-09 | GlaxoSmithKline Biologicals S.A. | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| GB0607088D0 (en) | 2006-04-07 | 2006-05-17 | Glaxosmithkline Biolog Sa | Vaccine |
| JP6087041B2 (ja) | 2006-01-27 | 2017-03-08 | ノバルティス アーゲー | 血球凝集素およびマトリックスタンパク質を含むインフルエンザウイルスワクチン |
| EP2357184B1 (en) | 2006-03-23 | 2015-02-25 | Novartis AG | Imidazoquinoxaline compounds as immunomodulators |
| EP2382987A1 (en) | 2006-03-24 | 2011-11-02 | Novartis Vaccines and Diagnostics GmbH | Storage of influenza vaccines without refrigeration |
| KR101541383B1 (ko) | 2006-03-30 | 2015-08-03 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 면역원성 조성물 |
| DK2054431T3 (da) | 2006-06-09 | 2012-01-02 | Novartis Ag | Konformere af bakterielle adhæsiner |
| EP2043682B1 (en) | 2006-07-17 | 2014-04-02 | GlaxoSmithKline Biologicals S.A. | Influenza vaccine |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| EP2497495B3 (en) | 2006-09-11 | 2021-02-17 | Seqirus UK Limited | Making influenza virus vaccines without using eggs |
| EP2679240A1 (en) | 2006-12-06 | 2014-01-01 | Novartis AG | Vaccines including antigen from four strains of influenza virus |
| TW200908994A (en) | 2007-04-20 | 2009-03-01 | Glaxosmithkline Biolog Sa | Vaccine |
| US20100183662A1 (en) | 2007-06-26 | 2010-07-22 | Ralph Leon Biemans | Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates |
| CN101784283A (zh) | 2007-06-27 | 2010-07-21 | 诺华有限公司 | 低添加流感疫苗 |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| GB0818453D0 (en) | 2008-10-08 | 2008-11-12 | Novartis Ag | Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom |
| EP2235532B1 (en) | 2007-12-24 | 2013-04-24 | Novartis AG | Assays for adsorbed influenza vaccines |
| US20120058149A1 (en) | 2009-03-05 | 2012-03-08 | Mccloskey Jenny Colleen | Treatment of infection |
| WO2011008974A2 (en) | 2009-07-15 | 2011-01-20 | Novartis Ag | Rsv f protein compositions and methods for making same |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| GB0913681D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| EA025152B1 (ru) | 2010-12-02 | 2016-11-30 | Бионор Иммуно Ас | Конструкция пептидного каркаса |
| MX346475B (es) | 2011-01-06 | 2017-03-22 | Bionor Immuno As | Peptidos inmunogenicos monomericos y multimericos. |
| EP2667892B1 (en) | 2011-01-26 | 2019-03-27 | GlaxoSmithKline Biologicals SA | Rsv immunization regimen |
| LT3275892T (lt) | 2011-05-13 | 2020-04-10 | Glaxosmithkline Biologicals S.A. | Struktūros prieš suliejimą rsv f antigenai |
| CN104619718A (zh) | 2012-06-06 | 2015-05-13 | 比奥诺尔免疫有限公司 | 源自病毒蛋白的肽用作免疫原和配药成分 |
| EP3313439A2 (en) | 2015-06-26 | 2018-05-02 | Seqirus UK Limited | Antigenically matched influenza vaccines |
| US12128100B2 (en) | 2018-11-13 | 2024-10-29 | Variation Biotechnologies Inc. | Immunogenic compositions for treatment of Hepatitis B |
| WO2021160887A1 (en) | 2020-02-14 | 2021-08-19 | Immunor As | Corona virus vaccine |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE70308T1 (de) * | 1984-09-12 | 1991-12-15 | Chiron Corp | Hybridpartikel-immunogene. |
| CN1049686C (zh) * | 1987-11-18 | 2000-02-23 | 希龙股份有限公司 | 非ａ和非ｂ肝炎病毒的诊断及疫苗 |
| AU3748489A (en) * | 1988-06-17 | 1990-01-12 | Genelabs Incorporated | Enterically transmitted non-a/non-b hepatitis viral agent |
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| SG48175A1 (en) * | 1989-07-25 | 1998-04-17 | Smithkline Beecham Biolog | Novel antigens and method for their preparation |
| CA2065287C (en) * | 1989-09-15 | 1999-12-21 | Tatsuo Miyamura | New hcv isolates |
| IL97985A0 (en) * | 1990-05-07 | 1992-06-21 | North American Vaccine Inc | Improved vaccine compositions |
| WO1992011291A1 (en) * | 1990-12-20 | 1992-07-09 | Smithkline Beecham Biologicals (S.A.) | Vaccines based on hepatitis b surface antigen |
-
1993
- 1993-03-23 MA MA23137A patent/MA22842A1/fr unknown
- 1993-03-23 MY MYPI93000533A patent/MY111880A/en unknown
- 1993-03-24 KR KR1019940703355A patent/KR100270134B1/ko not_active IP Right Cessation
- 1993-03-24 HU HU9402758A patent/HU221253B1/hu unknown
- 1993-03-24 DK DK93906601T patent/DK0633784T4/da active
- 1993-03-24 AT AT93906601T patent/ATE146678T1/de active
- 1993-03-24 WO PCT/EP1993/000712 patent/WO1993019780A1/en active IP Right Grant
- 1993-03-24 UA UA94105947A patent/UA44688C2/uk unknown
- 1993-03-24 NZ NZ249868A patent/NZ249868A/en not_active IP Right Cessation
- 1993-03-24 JP JP51704693A patent/JP3470719B2/ja not_active Expired - Lifetime
- 1993-03-24 ES ES93906601T patent/ES2098029T5/es not_active Expired - Lifetime
- 1993-03-24 EP EP93906601A patent/EP0633784B2/en not_active Expired - Lifetime
- 1993-03-24 CZ CZ942355A patent/CZ283424B6/cs not_active IP Right Cessation
- 1993-03-24 DE DE69306940T patent/DE69306940T3/de not_active Expired - Lifetime
- 1993-03-24 AU AU37516/93A patent/AU3751693A/en not_active Abandoned
- 1993-03-24 SK SK1152-94A patent/SK280160B6/sk not_active IP Right Cessation
- 1993-03-24 SG SG1996009183A patent/SG48375A1/en unknown
- 1993-03-24 RU RU94042386A patent/RU2121849C1/ru active
- 1993-03-24 CA CA002132833A patent/CA2132833C/en not_active Expired - Lifetime
- 1993-03-25 IL IL10516193A patent/IL105161A/en not_active IP Right Cessation
- 1993-03-25 AP APAP/P/1993/000502A patent/AP570A/en active
- 1993-03-26 CN CN93105232A patent/CN1072963C/zh not_active Expired - Lifetime
- 1993-03-26 SI SI9300149A patent/SI9300149B/sl unknown
- 1993-06-08 SA SA93130573A patent/SA93130573B1/ar unknown
-
1994
- 1994-09-26 FI FI944442A patent/FI110843B/sv not_active IP Right Cessation
- 1994-09-26 NO NO943571A patent/NO309458B1/no not_active IP Right Cessation
-
1996
- 1996-09-05 AU AU64457/96A patent/AU6445796A/en not_active Abandoned
- 1996-12-30 GR GR960403615T patent/GR3022174T3/el unknown
-
1998
- 1998-03-19 HK HK98102341A patent/HK1003218A1/xx unknown
-
1999
- 1999-06-10 AU AU33974/99A patent/AU3397499A/en not_active Abandoned
-
2002
- 2002-01-02 AU AU10008/02A patent/AU767755B2/en not_active Expired
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI110843B (sv) | Förfarande för framställning av ett hepatitvaccin innehållande 3-O-deacylererad monofosforyllipid A | |
| FI110844B (sv) | Förfarande för framställning av 3-O-deacylerad monofosforyllipid A | |
| AP766A (en) | A vaccine based on hepatitis B antigen. | |
| US20020172692A1 (en) | Vaccine composition against malaria | |
| US6893644B2 (en) | Hepatitis vaccines containing 3-O-deacylated monophoshoryl lipid A | |
| US20030133944A1 (en) | Vaccine composition against malaria | |
| US20020192224A1 (en) | Hepatitis b vaccine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MA | Patent expired |